1. Scrip

China CAR-T Front-Runner Allegations Reveal Soft Underbelly Of Development Race

 
• By Brian Yang

A report from a short-seller group accuses Chinese firm Nanjing Legend of intentionally omitting clinical data for its CAR-T candidate, an allegation the company has refuted while global partner J&J says it remains "optimistic" about the product and conducted "careful" reviews of the data.

Destruction of leukaemia cell, conceptual image. 3D illustration which can be used to illustrate blood cancer treatment
Report Claims Nanjing Legend Used Selected Data For CAR-T Asset Licensed To Janssen

Legend Biotech Corp. has been leading the pack in a sizzling CAR-T development race in China, its most advanced asset in the field LCAR-B38M grabbing headlines at last year's American Society of Clinical Oncology (ASCO) meeting with a 100% overall response rate in multiple myeloma, followed by a global partnership deal with Janssen R&D LLC for $350m upfront.

The stunning response and overall survival rates for the drug made the previously little-known company from Nanjing a dark horse at the largest oncology

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

More from Focus On Asia